Basic study for personalized medicine of Graves' disease
| Project/Area Number |
23591909
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
別所 竜蔵 日本医科大学, 医学部, 准教授 (60281432)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | バセドウ病 / 個別化医療 / SNP / 薬物代謝酵素 / オーダーメイド医療 / ゲノム |
|---|
| Research Abstract |
We analyzed the gene of FMO3 in order to examine the possibility of the responsible gene of the agranulacytosis onset with Thiamazole(MMI) of the patients with Graves' disease. We analyzed the single nucleatide polymorphism(SNP) and all Exons of FMO3. The variations with four places of amino acid alterations were found. However, we are thought to be less likely to be associated with an onset-risk of agranulacytosis becasuse these variations are common in the general population.
It is extremely important to continue the search of the biomarker judging a side effect of MMI for the Graves' disease patients.
|
Report
(4 results)
Research Products
(5 results)
